xAnts

Nexalin Technology has welcomed a key legislative provision within a U.S. House Appropriations Committee report that supports expanded research into non-invasive deep brain neurostimulation (nDBS) for veterans struggling with treatment-resistant trauma. The move, announced earlier today, directs the Department of Veterans Affairs (VA) to prioritize and facilitate further evaluation of nDBS technologies.

The report language specifically encourages the VA to explore the potential of nDBS for veterans experiencing persistent and debilitating conditions despite conventional treatments. Nexalin Technology, a company focused on developing nDBS solutions, views this as a significant step forward for veterans’ mental health and a validation of their own research efforts.

nDBS is a non-surgical technique that uses focused electrical stimulation to target specific areas of the brain. It's considered a promising alternative to invasive brain surgery for certain neurological and psychiatric disorders. The U.S. House’s action aims to accelerate the understanding of nDBS's efficacy and safety within the veteran population, who often face unique challenges related to PTSD and other trauma-related conditions.

Nexalin Technology commended the U.S. House for its recognition of the potential benefits of nDBS. The company highlighted the critical need for innovative treatments to address the unmet needs of veterans and expressed optimism that this legislative support will spur further research and ultimately lead to improved outcomes for those who served.

While the report language is not binding legislation, it carries significant weight and signals a clear direction for the VA’s research priorities. The full Appropriations bill is expected to undergo further review and consideration before final passage, but Nexalin Technology remains hopeful that this provision will be retained.